IMTX — Immatics N.V.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1809196 ·
Last close
$6.29
Market Cap
$957.50M
52W High
$12.41
52W Low
$6.06
ADV30
1,161,640
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 6,923,000 | — | -78,542,000 | -76,022,000 | 565,723,000 | 276,614,000 | 127,224,000 |
| Jun 2026 | 9,144,000 | — | -67,204,000 | -62,492,000 | 485,735,000 | 232,459,000 | 86,110,000 |
| Mar 2026 | 7,612,000 | — | -66,064,000 | -57,814,000 | 543,264,000 | 301,332,000 | 87,463,000 |
| Dec 2025 | 19,761,000 | — | -38,881,000 | -35,698,000 | 562,337,000 | 345,918,000 | 78,238,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-205,869,000
Investing CF
$57,494,000
Financing CF
$119,122,000
CapEx
$-3,746,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.89
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-906,294,000
Inventory
—
Receivables
$6,664,000
ST Investments
$160,891,000
EBIT TTM
$-205,896,000
Pretax Income TTM
$-206,764,000
Interest Exp TTM
$868,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$41,704,000
EBITDA
$-218,028,992
Free Cash Flow
$-126,542,624
Enterprise Value
$822,760,896
Total Cash
$393,350,016
Total Debt
$14,606,000
Shares Out
152,225,077
Trailing EPS
$-1.85
Book Value
$3.39
ROE
-47.8%
ROA
-26.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 48,266,000 | -182,016,000 | -196,447,000 | 562,337,000 | 78,238,000 | 484,099,000 | -176,626,000 |
| Dec 2024 | 155,835,000 | -38,615,000 | 15,218,000 | 696,146,000 | 121,304,000 | 574,842,000 | -158,030,000 |
| Dec 2023 | 53,997,000 | -101,725,000 | -94,649,000 | 509,965,000 | 292,347,000 | 217,618,000 | 18,228,000 |
| Dec 2022 | 172,831,000 | 29,954,000 | 27,703,000 | 407,820,000 | 204,467,000 | 203,353,000 | 100,131,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.07
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.00 · spot: $6.10 · call volume: 156 · put volume: 9Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ODTX | Odyssey Therapeutics, Inc. | $931.07M | $19.37 | — |
| PRME | Prime Medicine, Inc. | $854.20M | $3.84 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.09B | $74.18 | — |
| BBTX | Bambusa Therapeutics, Inc. | $832.91M | $16.35 | — |
| MGTX | MeiraGTx Holdings plc | $826.80M | $8.46 | — |
News headlines (Yahoo Finance, 1h cache)
Immatics (IMTX) Reports Q3 Loss, Lags Revenue Estimates
2026-11-10 12:15 · Yahoo
Immatics: Q3 Earnings Snapshot
2026-11-10 12:13 · Yahoo
Immatics Announces Third Quarter 2026 Financial Results and Business Update
2026-11-10 12:00 · Yahoo
Immatics (IMTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2026-11-09 14:00 · Yahoo
Immatics (IMTX) PRAME Data Puts A Pricey Valuation Back In Focus
2026-11-01 00:21 · Yahoo
Immatics (IMTX) Stock Looks Stretched As PRAME Trial Data Impresses
2026-10-29 01:09 · Yahoo
Should Updated Trial Results Require Action From Immatics (IMTX) Investors?
2026-10-25 03:20 · Yahoo
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
2026-10-24 06:30 · Yahoo
Immatics and 4 More Stocks See Action From Activist Investors
2026-09-04 22:59 · Yahoo
Immatics Announces $150 Million Underwritten Offering
2026-08-25 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.